RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PCI Biotech Holding A Stock

PCI Biotech Holding A Revenue 2024

PCI Biotech Holding A Revenue

7.27 M NOK

Ticker

PCIB.OL

ISIN

NO0010405640

WKN

A0Q2FS

In 2024, PCI Biotech Holding A's sales reached 7.27 M NOK, a 143.24% difference from the 2.99 M NOK sales recorded in the previous year.

The PCI Biotech Holding A Revenue history

YEARREVENUE (undefined NOK)GROSS MARGIN (%)
2024e7.2765,31
20232.99158,86
20224.75100,00
20216.2799,95
20207.3764,47
20199.3950,57
20189.5949,56
201710.2546,34
201610.4845,35
201510.4745,38
20147.365,10
20136.6871,11
20126.7770,16
20117.4264,02
201010.4445,50
20098.6155,17
20087.3764,45
2007--

PCI Biotech Holding A Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PCI Biotech Holding A, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PCI Biotech Holding A from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PCI Biotech Holding A’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PCI Biotech Holding A. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PCI Biotech Holding A’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PCI Biotech Holding A’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PCI Biotech Holding A’s growth potential.

PCI Biotech Holding A Revenue, EBIT and net profit per share

DatePCI Biotech Holding A RevenuePCI Biotech Holding A EBITPCI Biotech Holding A Net Income
2024e7.27 M NOK-88.81 M NOK-83.08 M NOK
20232.99 M NOK-22.24 M NOK-20.32 M NOK
20224.75 M NOK-56.45 M NOK-55.1 M NOK
20216.27 M NOK-86.03 M NOK-88.39 M NOK
20207.37 M NOK-82.12 M NOK-72.24 M NOK
20199.39 M NOK-88.8 M NOK-88.75 M NOK
20189.59 M NOK-44.52 M NOK-34.78 M NOK
201710.25 M NOK-43.43 M NOK-42.84 M NOK
201610.48 M NOK-33.03 M NOK-32.18 M NOK
201510.47 M NOK-32.63 M NOK-31.92 M NOK
20147.3 M NOK-36.47 M NOK-35.84 M NOK
20136.68 M NOK-29.33 M NOK-27.61 M NOK
20126.77 M NOK-27.35 M NOK-25.26 M NOK
20117.42 M NOK-17.08 M NOK-13.75 M NOK
201010.44 M NOK-16.24 M NOK-13.94 M NOK
20098.61 M NOK-17.69 M NOK-15.02 M NOK
20087.37 M NOK-12.14 M NOK-11.38 M NOK
20070 NOK0 NOK0 NOK

PCI Biotech Holding A stock margins

The PCI Biotech Holding A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PCI Biotech Holding A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PCI Biotech Holding A.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PCI Biotech Holding A's sales revenue. A higher gross margin percentage indicates that the PCI Biotech Holding A retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PCI Biotech Holding A's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PCI Biotech Holding A's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PCI Biotech Holding A's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PCI Biotech Holding A. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PCI Biotech Holding A's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PCI Biotech Holding A Margin History

PCI Biotech Holding A Gross marginPCI Biotech Holding A Profit marginPCI Biotech Holding A EBIT marginPCI Biotech Holding A Profit margin
2024e100 %-1,221.14 %-1,142.36 %
2023100 %-743.85 %-679.43 %
2022100 %-1,188.36 %-1,159.89 %
202199.95 %-1,371.42 %-1,409.07 %
2020100 %-1,114.56 %-980.44 %
2019100 %-945.52 %-944.91 %
2018100 %-464.47 %-362.86 %
2017100 %-423.72 %-417.96 %
2016100 %-315.29 %-307.25 %
2015100 %-311.73 %-304.98 %
2014100 %-499.82 %-491.16 %
2013100 %-439.07 %-413.32 %
2012100 %-403.99 %-373.12 %
2011100 %-230.19 %-185.31 %
2010100 %-155.56 %-133.52 %
2009100 %-205.46 %-174.45 %
2008100 %-164.72 %-154.41 %
2007100 %0 %0 %

PCI Biotech Holding A Aktienanalyse

What does PCI Biotech Holding A do?

PCI Biotech Holding ASA is a biopharmaceutical company based in Norway that focuses on the clinical development of drugs based on the so-called "Photochemical Internalization" (PCI) technology. The company was founded in 2000 as a spin-off from the Norwegian Cancer Society. The PCI technology, which is based on the use of light and chemicals to transport drugs into cells, was developed by Norwegian researchers in the 1990s. Since then, PCI Biotech has been working in collaboration with various research institutions and pharmaceutical companies to optimize this technology and advance its application in medicine. PCI Biotech's business model is based on providing its PCI technology and expertise to partners in research and industry. At the same time, the company also conducts its own clinical research on drugs based on the PCI technology. The goal is to develop drugs that are effective in various forms of cancer and other serious diseases. PCI Biotech is divided into two main divisions: the project department, which works on the development of its own drugs, and the service department, which licenses its PCI technology to third parties. One significant product of the project department is the drug "Amphinex," which is used in the treatment of pancreatic cancer. Amphinex is administered to patients in combination with chemotherapy to enhance the effectiveness of the chemotherapy. Amphinex activates the PCI technology in cancer cells, thereby facilitating the penetration of the chemotherapeutic agent into the cells. Other projects in the company's pipeline include drugs for the treatment of prostate cancer and skin cancer, as well as targeted destruction of tumor cells in the brain. The service department offers various solutions for the academic and industrial sectors. The PCI technology can be used in the development of drugs for the treatment of other diseases, such as viral infections or inflammatory diseases. Furthermore, the PCI technology can also be utilized in imaging or diagnostics. Overall, PCI Biotech is a company specialized in the development of innovative drugs. By using the PCI technology, drugs can be delivered more specifically and effectively into cells, opening up new possibilities in cancer treatment and other areas of medicine. PCI Biotech has become a significant player in clinical research in recent years and works closely with other research institutions and pharmaceutical companies to optimize their technology and explore new application areas. PCI Biotech Holding A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding PCI Biotech Holding A's Sales Figures

The sales figures of PCI Biotech Holding A originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing PCI Biotech Holding A’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize PCI Biotech Holding A's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in PCI Biotech Holding A’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about PCI Biotech Holding A stock

How much revenue did PCI Biotech Holding A generate this year?

PCI Biotech Holding A has achieved a revenue of 7.27 M NOK this year.

How much was the turnover of the company PCI Biotech Holding A compared to the previous year?

The revenue of PCI Biotech Holding A has increased by 143.24% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of PCI Biotech Holding A?

The revenue of PCI Biotech Holding A is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of PCI Biotech Holding A measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of PCI Biotech Holding A so important for investors?

The revenue of PCI Biotech Holding A is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does PCI Biotech Holding A pay?

Over the past 12 months, PCI Biotech Holding A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PCI Biotech Holding A is expected to pay a dividend of 0 NOK.

What is the dividend yield of PCI Biotech Holding A?

The current dividend yield of PCI Biotech Holding A is .

When does PCI Biotech Holding A pay dividends?

PCI Biotech Holding A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PCI Biotech Holding A?

PCI Biotech Holding A paid dividends every year for the past 0 years.

What is the dividend of PCI Biotech Holding A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is PCI Biotech Holding A located?

PCI Biotech Holding A is assigned to the 'Health' sector.

Wann musste ich die Aktien von PCI Biotech Holding A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PCI Biotech Holding A from 9/18/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did PCI Biotech Holding A pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of PCI Biotech Holding A in the year 2023?

In the year 2023, PCI Biotech Holding A distributed 0 NOK as dividends.

In which currency does PCI Biotech Holding A pay out the dividend?

The dividends of PCI Biotech Holding A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PCI Biotech Holding A

Our stock analysis for PCI Biotech Holding A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PCI Biotech Holding A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.